Business Context and Reporting Period
This Form 8-K, dated May 5, 2016, reports a material definitive agreement and equity investment involving Wave Life Sciences Ltd. (Wave). The filing details a strategic collaboration with Pfizer Inc. focused on the discovery, development, and commercialization of stereopure oligonucleotide therapeutics for hepatic targets.
Key Financial Metrics and Transaction Terms
- Upfront Payment: Pfizer agreed to pay $40 million upfront.
- Equity Investment: $30 million of the upfront payment is an equity investment by a Pfizer affiliate purchasing 1,875,000 ordinary shares at $16 per share (a 9.36% premium over the May 4, 2016 closing price).
- Cash Component: $10 million of the upfront payment is cash.
- Potential Milestones: Wave may earn up to $871 million in research, development, and commercial milestone payments, contingent on the successful development and commercialization of up to five products.
- Royalties: Tiered royalties on sales of products resulting from the collaboration, up to low double-digits.
- Ownership Stake: Following the transaction, Pfizer beneficially owns approximately 8% of Wave's outstanding ordinary shares.
Material Changes and Strategic Impact
The primary material change is the entry into a four-year research term collaboration covering up to five programs ("Pfizer Programs"). Pfizer has already declared two hepatic targets, including Wave's Apolipoprotein C-III program, with three more to be declared within 18 months. Wave retains rights to intellectual property if Pfizer declines to exercise its option on a clinical candidate. Additionally, Wave received a non-exclusive, royalty-bearing license to use Pfizer's hepatic targeting technology for its own programs outside the collaboration.
Outlook, Liquidity, and Risks
Liquidity and Runway: Management expects that existing cash combined with the $40 million upfront payment will fund operating expenses and capital expenditures into 2019.
Restrictions: Pfizer is subject to a standstill agreement regarding the acquisition of additional Wave shares for a specified period. The Pfizer affiliate's shares are subject to a lock-up restriction.
Risks and Contingencies: The filing includes forward-looking statements regarding the ability to advance candidates to clinical selection and Pfizer's decision to exercise options. Actual results may differ due to risks described in Wave's 2015 Form 10-K. The agreement allows for termination by either party for convenience with 90 days' notice or for material breach.
Investor Verification Checklist
- Verify the exact terms of the standstill agreement and lock-up period for Pfizer's shares.
- Confirm the specific definitions of the milestone triggers for the potential $871 million in payments.
- Review the full text of the Research, License and Option Agreement (to be filed as an exhibit to the Q2 2016 Form 10-Q) for redacted confidential terms.
- Assess the impact of the 8% ownership stake on future corporate governance and potential M&A activity.
- Monitor the declaration of the remaining three hepatic targets within the 18-month window.